A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

April 4, 2020

Study Completion Date

April 4, 2020

Conditions

Healthy Volunteers

Interventions

DRUG

TAK-831 Oral Tablet

TAK-831 tablet.

DRUG

[14C]TAK-831 IV Infusion

\[14C\]TAK-831 IV infusion.

DRUG

[14C]TAK-831 Oral Suspension

\[14C\]TAK-831 oral suspension.

Trial Locations (1)

Celerion, Lincoln